Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study
Abstract Background This study aimed to evaluate the efficacy and the safety of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing neutropenia in metastatic colorectal cancer (mCRC) patients that received fluorouracil, leucovorin, oxaliplatin, and irinote...
Main Authors: | Yusuke Kitagawa, Hiroki Osumi, Eiji Shinozaki, Yumiko Ota, Izuma Nakayama, Takeshi Suzuki, Takeru Wakatsuki, Mariko Ogura, Akira Ooki, Daisuke Takahari, Mitsukuni Suenaga, Keisho Chin, Kensei Yamaguchi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-04-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-020-06864-8 |
Similar Items
-
FOLFOXIRI Resistance Induction and Characterization in Human Colorectal Cancer Cells
by: George M. Ramzy, et al.
Published: (2022-09-01) -
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature
by: Stein Alexander, et al.
Published: (2012-08-01) -
Simultaneous treatment with carbimazole and granulocyte-colony stimulating factor in a patient with thyrotoxicosis and carbimazole induced neutropenia
by: Talapatra Indrajit, et al.
Published: (2006-12-01) -
FOLFOXIRI in Pregnant Women with Colorectal Cancer: A Case Report and Review of the Literature
by: Landon Kozai, et al.
Published: (2022-04-01) -
Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab
by: Shenglin Li, et al.
Published: (2023-03-01)